These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26650686)

  • 1. An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones.
    Massarotti A; Coluccia A
    J Mol Graph Model; 2016 Jan; 63():49-56. PubMed ID: 26650686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
    Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
    J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
    Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
    Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
    J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
    Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
    J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
    Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
    Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unconventional plasticity of HIV-1 reverse transcriptase: how inhibitors could open a connection "gate" between allosteric and catalytic sites.
    Bellucci L; Angeli L; Tafi A; Radi M; Botta M
    J Chem Inf Model; 2013 Dec; 53(12):3117-22. PubMed ID: 24256065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular insight on the binding of NNRTI to K103N mutated HIV-1 RT: molecular dynamics simulations and dynamic pharmacophore analysis.
    Nizami B; Sydow D; Wolber G; Honarparvar B
    Mol Biosyst; 2016 Oct; 12(11):3385-3395. PubMed ID: 27722739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Adjacent NNRTI Binding Pocket in Multi-mutated HIV1- RT Enzyme Model: An in silico Study.
    Kamil RF; Debnath U; Verma S; Prabhakar YS
    Curr HIV Res; 2018; 16(2):121-129. PubMed ID: 29651941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
    Liu J; He X; Zhang JZ
    J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine.
    Bhakat S; Martin AJ; Soliman ME
    Mol Biosyst; 2014 Aug; 10(8):2215-28. PubMed ID: 24931725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide.
    De Martino G; La Regina G; Ragno R; Coluccia A; Bergamini A; Ciaprini C; Sinistro A; Maga G; Crespan E; Artico M; Silvestri R
    Antivir Chem Chemother; 2006; 17(2):59-77. PubMed ID: 17042328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants.
    Silvestri R; Artico M
    Curr Pharm Des; 2005; 11(29):3779-806. PubMed ID: 16305512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemometrical identification of mutations in HIV-1 reverse transcriptase conferring resistance or enhanced sensitivity to arylsulfonylbenzonitriles.
    Rodríguez-Barrios F; Gago F
    J Am Chem Soc; 2004 Mar; 126(9):2718-9. PubMed ID: 14995186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
    Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
    Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
    Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.